# Neurocrine Biosciences (NBIX)

Sector: Biotech: neurology, psychiatry and endocrine medicines

| Field | Value |
|---|---|
| Price | $150.57 |
| Market cap | $15B |
| Intrinsic value source | AI estimate |
| Data as of | 2026-11-20 |
| Next earnings | 2027-02-02 (estimate) |

Analysts: Very bullish

Picks: Top pick

Discount category: Below intrinsic value

## In short

The market fears that Medicare price rules and competition will cut the INGREZZA profit, and steady INGREZZA sales with fast CRENESSITY and VYKAT XR growth and good Phase 3 results in 2027 can lift its value.

## Themes and gap

- Themes: Regulation and courts (regulation-legal)
- Gap type: Can close (closable)
- Why: The 2027 guidance in early 2027 and the Phase 3 results during 2027 show within about a year whether growth continues beyond INGREZZA.

## About

Neurocrine Biosciences (NBIX) is a US biopharmaceutical company that develops and sells medicines for neurological, psychiatric and endocrine disorders. INGREZZA (valbenazine) treats tardive dyskinesia and chorea associated with Huntington's disease. CRENESSITY (crinecerfont) treats classic congenital adrenal hyperplasia. VYKAT XR (diazoxide choline) treats hyperphagia in Prader-Willi syndrome. Neurocrine got VYKAT XR when it bought Soleno Therapeutics on May 18, 2026. AbbVie sells two medicines from Neurocrine research for endometriosis and uterine fibroids. Total revenue was $1,123 million in Q3 2026, and INGREZZA was $801 million of it.

## Thesis

Investors give Neurocrine a moderate multiple because most of its profit still comes from one medicine. INGREZZA was $801 million of $1,123 million of revenue in Q3 2026. Its competitor AUSTEDO gets a negotiated Medicare price from 2027, which can add price pressure on INGREZZA. INGREZZA can itself be selected for Medicare price negotiation in 2027, with a new price from 2029, and generic versions can enter from March 1, 2038. Neurocrine also spent about $2.9 billion in cash on Soleno, and its research costs rise for two Phase 3 programs. The AI estimate assumes revenue of about $4.9 billion in 2027. For the price to rise, three things must be true. INGREZZA must keep volume growth and a stable net price in 2027. CRENESSITY and VYKAT XR must keep growing from $211 million and $107 million a quarter in Q3 2026. The Phase 3 studies of osavampator in major depressive disorder and direclidine in schizophrenia must give good results in 2027. The R&D Day on December 15, 2026, the Q4 2026 results with the 2027 guidance in early 2027, and the Phase 3 results during 2027 are the next tests.

## Checkpoints

- Dec 15, 2026: R&D Day. Status: Pending. Watch: Neurocrine gives clear timing for the Phase 3 results of osavampator and direclidine in 2027 and new programs that add value, and this passes; delays of the Phase 3 programs fail.
- Feb 2, 2027 (estimate): Q4 2026 results and 2027 guidance. Status: Pending. Watch: 2026 INGREZZA sales are within $2.900 to $2.925 billion and the 2027 guidance shows growth after the new AUSTEDO Medicare price, and this passes; a miss or a 2027 decline fails.
- 2027 (estimate): Phase 3 results of osavampator and direclidine. Status: Pending. Watch: At least one of the two Phase 3 programs meets its main goal in 2027, and this passes; two failures fail.

## Valuation

The intrinsic value for Neurocrine Biosciences is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Neurocrine with the SEC. The method is a multiple of 2027 earnings per share after stock-based compensation, plus net cash per share. The Q3 2026 release of November 2, 2026 (Form 8-K) gives total revenue of $1,123 million for Q3 2026: INGREZZA $801 million, CRENESSITY $211 million and VYKAT XR $107 million. It raises the 2026 INGREZZA guidance to $2,900 to $2,925 million, and it gives 2026 non-GAAP R&D of $1,140 to $1,190 million and non-GAAP SG&A of $1,290 to $1,310 million. Stock-based compensation was $54.3 million in Q3 2026. The estimate counts it as a cost. It leaves out the amortization of the VYKAT XR rights and the costs of the Soleno purchase, because the purchase price is already paid. The Q3 2026 10-Q gives cash, cash equivalents and marketable securities of $790 million and no borrowings at September 30, 2026, and 101,218,643 shares outstanding at October 26, 2026. The estimate uses the diluted weighted average of 105.2 million shares in Q3 2026, so net cash is $7.51 per share. The 2027 revenue, the operating margins after stock-based compensation, a tax rate of 21%, the multiples and the weights are assumptions. The low case assumes revenue of $4,600 million and a margin of 30%, because INGREZZA loses net price after the negotiated Medicare price of AUSTEDO starts in 2027, at 12 times. It gives $131.87 per share. The base case assumes $4,900 million and 35%, at 14 times. It gives $187.81 per share. The high case assumes $5,200 million and 38%, with faster growth of CRENESSITY and VYKAT XR, at 16 times. It gives $244.93 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $188.11 per share. The cases give no separate value to the Phase 3 programs of osavampator and direclidine. Intangible assets are the main source of advantage. Under the 2023 settlements, generic INGREZZA can enter the US market from March 1, 2038, or earlier in certain circumstances (2025 10-K). CRENESSITY has seven years of orphan drug exclusivity. But AUSTEDO competes with INGREZZA, INGREZZA can be selected for Medicare price negotiation in 2027 for prices from 2029, and Alvogen filed for a generic VYKAT XR in September 2026.

As of 2026-11-14.

Sources:

- https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/q3-2026xearningsrelease.htm
- https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/nbix-20260930.htm
- https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm
- https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/d94926d8k.htm

## Balance sheet

- Cash: $790M
- Debt: $0.0M
- Net cash: $790M
- Undrawn credit line: $1.0B, to May 2031

At September 30, 2026, Neurocrine had cash, cash equivalents and marketable securities of $790 million, down from $2,543 million at December 31, 2025, because it paid about $2.9 billion in cash for Soleno in May 2026. It had no borrowings. The senior secured revolving credit facility of $1.0 billion was fully available and matures on May 14, 2031. Its covenants set a maximum total net leverage ratio of 3.75 times and a minimum interest coverage of 2.00 times. Total assets were $5,627.4 million and stockholders' equity was $3,878.7 million. $174.2 million remained under the 2025 share repurchase program.

As of 2026-09-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/q3-2026xearningsrelease.htm
- https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/nbix-20260930.htm
- https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/d94926d8k.htm

## Dividends

Neurocrine Biosciences does not pay a dividend.

Source: company filings and market data, read on 2026-11-13.

## Recent events

- 2026-11-02: Neurocrine reported Q3 2026 results. Total revenue grew 41% to $1,123 million. INGREZZA sales were $801 million (up 17%), CRENESSITY $211 million and VYKAT XR $107 million. Neurocrine raised its 2026 INGREZZA guidance to $2.900 to $2.925 billion and set an R&D Day for December 15, 2026.
- 2026-09-25: Eiry W. Roberts, M.D., the former Chief Medical Officer, rejoined the executive team as Chief Medical Officer.
- 2026-07-30: Neurocrine reported Q2 2026 results. Total revenue grew 39% to $959 million, and it raised its 2026 INGREZZA guidance to $2.825 to $2.875 billion.
- 2026-05-18: Neurocrine completed the purchase of Soleno Therapeutics for about $2.9 billion in cash and added VYKAT XR. It recorded about $2.2 billion of VYKAT XR rights, which it amortizes over 16 years.
- 2026-05-14: Neurocrine entered into a senior secured revolving credit facility of $1.0 billion. It borrowed $600 million for the Soleno purchase and repaid it in June 2026.
- 2026-05-05: Neurocrine reported Q1 2026 net product sales of $811.0 million, up 44%. INGREZZA sales were $656.9 million and CRENESSITY sales were $153.3 million.
- 2026-04-05: Neurocrine agreed to buy Soleno Therapeutics for $53.00 per share in cash, through a tender offer.
- 2026-02-11: Neurocrine reported 2025 net product sales of $2.83 billion, up 22%. INGREZZA sales were $2.51 billion and CRENESSITY sales were $301.2 million. It guided 2026 INGREZZA sales to $2.7 to $2.8 billion.

## Latest news and filings

- Last earnings: 2026-11-02 (8-K: https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/)
- Next earnings: 2027-02-02 (expected; the company has not confirmed it)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-11-02 | 10-Q | Quarterly report for the period ended Sep 30, 2026 | 2026-09-30 | nbix-20260930 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/nbix-20260930.htm |
| 2026-11-02 | 8-K | Earnings release |  | nbix-20261102 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/ |
| 2026-09-28 | 8-K | Change of directors or officers |  | nbix-20260925 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm |
| 2026-07-31 | 10-Q | Quarterly report for the period ended Jun 30, 2026 | 2026-06-30 | nbix-20260630 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm |
| 2026-07-30 | 8-K | Earnings release |  | nbix-20260730 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/ |
| 2026-05-28 | 8-K | Change of directors or officers and Shareholder vote results |  | nbix-20260527 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/nbix-20260527.htm |
| 2026-05-18 | 8-K | New material agreement and Acquisition or sale completed |  |  | https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/d94926d8k.htm |
| 2026-05-05 | 10-Q | Quarterly report for the period ended Mar 31, 2026 | 2026-03-31 | nbix-20260331 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000026/nbix-20260331.htm |
| 2026-05-05 | 8-K | Earnings release |  | nbix-20260505 | https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/ |
| 2026-04-06 | 8-K | New material agreement |  |  | https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/d110123d8k.htm |

Every filing on SEC EDGAR (CIK 914475): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000914475&type=&dateb=&owner=include&count=40

## Risks

- High: INGREZZA was about 71% of revenue in Q3 2026. INGREZZA can be selected for Medicare price negotiation in 2027, with a new price from 2029, and the negotiated price of AUSTEDO from 2027 can add price pressure.
- Medium: Under the 2023 patent settlements, generic INGREZZA can enter the US market from March 1, 2038, or earlier in certain circumstances. In September 2026, Alvogen filed for approval of a generic VYKAT XR, and Neurocrine sued it.
- Medium: The Phase 3 programs of osavampator and direclidine can fail. Neurocrine guides 2026 GAAP R&D of $1,275 to $1,325 million.
- Medium: VYKAT XR must grow to justify its price of about $2.9 billion. A class action filed on March 6, 2026 against Soleno and its management is still open.
- Low: Cash and marketable securities fell to $790 million at September 30, 2026, from $2,543 million at the end of 2025, after the Soleno purchase.

## Links

- Page: https://picks.utilarium.app/company/NBIX/
- History of changes: https://picks.utilarium.app/company/NBIX/history/
- JSON with full history: https://picks.utilarium.app/data/company/NBIX.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
